FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
ConsumerAffairs2d
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
NJBIZ23h
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior ...
조선일보9d
Johnson & Johnson CEO forecasts Reklaza sales will surpass 7 trillion won annually
Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...
Latest Medicare price drug negotiations includes Ozempic, Wegovy
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
BioPharma Dive10d
J&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) ...
The Hindu27d
U.S. Food and Drug Administration proposes new testing rules to ensure cosmetics are asbestos-free
The proposal from the Food and Drug Administration on Thursday (December ... It follows years of lawsuits against Johnson & Johnson and other companies alleging links between talc-based baby ...